Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
Go back to Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting| ImaRx Therapeutics, Inc. (NASDAQ: IMRX) | Delayed: 4.19 +0.07 (1.70%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $4.12 | 52 Week High | $0.04 | |||
| Open | $4.11 | 52 Week Low | $0.00 | |||
| Day High | $4.30 | P/E | N/A | |||
| Day Low | $4.07 | EPS | $-0.09 | |||
| Volume | 1,547,973 | |||||
